Stock listing

Zealand Pharma A/s

Selected listing: ZEALC · AQUISEU · DKK · GB

Zealand Pharma A/s (Aquis:ZEALC), Health Technology. Latest release Oct 1, 2026: Zealand Pharma A/S : announces Boehringer Ingelheim's survodutide achieves up…

ZEALC:AQUISEUDKKGBUpdated October 2, 2026

Ticker: Aquis:ZEALC
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: Aquis
Currency: DKK

Latest news from Zealand Pharma A/s

Zealand Pharma A/S : announces Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes

October 1, 2026

Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology

September 29, 2026

Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)

September 28, 2026

Zealand Pharma - Transactions related to share buy-back program (week 38, 2026)

September 21, 2026

Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome

September 18, 2026

All Zealand Pharma A/s news →

Research Zealand Pharma A/s

Zealand Pharma A/s company profile

View the public company page for Zealand Pharma A/s on 6ix.

Zealand Pharma A/s news

Read company news and market updates connected to Zealand Pharma A/s.

Zealand Pharma A/s investor events

Find investor webinars, events, and replay context for Zealand Pharma A/s.